FORMULATION ARTICLES

FORMULATION VIDEOS

Single-pass tangential flow filtration effectively concentrates mRNA-LNPs and removes ethanol while maintaining quality. See how this approach produced LNPs with 4.2-fold higher in vitro potency.

A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.

New technologies for the encapsulation of nucleic acids, such as FDmiX, can potentially overcome limitations of currently available standard mixing technologies.

Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS